Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer
29 Octobre 2018 - 9:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo, has named Glenn
Goddard its executive vice president and chief financial officer.
Mr. Goddard will be a member of Intellia’s executive management
team and will oversee all financial functions and investor
relations, as well as information technologies and facilities.
“Glenn’s background in emerging biotech companies and experience
as a financial and business leader will be great assets to our
growing company, and will be important as Intellia implements its
full-spectrum genome editing strategy,” said Intellia President and
Chief Executive Officer John Leonard, M.D. “As Intellia moves
toward the clinic and transitions from an early- to mid-stage
biotech company, we are pleased to further augment our in-house
expertise with Glenn’s proven track record of being part of
leadership teams that have successfully guided therapeutics for
genetic diseases from preclinical efforts through clinical
development.”
Mr. Goddard joins Intellia with nearly 20 years of experience
leading financial and business support operations for biotechnology
companies, including strategic planning, fundraising, investor
relations, financial reporting and controls, information
technologies and facilities. Before Intellia, Mr. Goddard was the
chief financial officer at Generation Bio Company, where he led all
financial functions, investor relations, information technologies
and facilities. Previously, as the senior vice president of finance
and principal financial officer at Agios Pharmaceuticals, Mr.
Goddard helped lead the transition from an early-stage research
company to a commercial-ready organization, including progressing
the company’s lead candidate through clinical trials.
Additionally, he led Agios’ strategic financing efforts, raising
more than $700 million in equity financings. Prior to Agios, Mr.
Goddard held various senior-level financial management positions at
both Archemix, a privately held oligonucleotide platform-based
biopharmaceutical company, and Immunogen, a publicly traded
oncology-focused biopharmaceutical company. Mr. Goddard earned a
bachelor of science in accountancy from Bentley College and is a
certified public accountant.
“I look forward to joining Intellia at this exciting time and
helping the team achieve our mission of developing curative
medicines based on its novel CRISPR/Cas9 platform,” said Mr.
Goddard.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through improved cell therapies that can treat cancer
and immunological diseases, or can replace patients’ diseased
cells. The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more
about Intellia Therapeutics and CRISPR/Cas9
at intelliatx.com and follow us on Twitter
@intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements” of
Intellia Therapeutics, Inc. (“Intellia”) within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, express
or implied statements regarding our growth as a company and the
anticipated contribution of the members of our board of directors
and our executives to our operations and progress.
Any forward-looking statements in this presentation are based on
management’s current expectations and beliefs of future events, and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to: risks related to
Intellia’s ability to protect and maintain our intellectual
property position; risks related to the ability of our licensors to
protect and maintain their intellectual property position;
uncertainties related to the initiation and conduct of studies and
other development requirements for our product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed and commercialized; the risk that the
results of preclinical studies will not be predictive of future
results in connection with future studies; the risk that Intellia’s
collaborations with Novartis or Regeneron or its
other ex vivo collaborations will not continue or will not be
successful; and risks related to the competitive landscape. For a
discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Intellia’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in Intellia’s
most recent annual report on Form 10-K and quarterly reports on
Form 10-Q filed with the Securities and Exchange Commission,
as well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with
the Securities and Exchange Commission. All information in
this presentation is as of the date of the release,
and Intellia Therapeutics undertakes no duty to update
this information unless required by law.
Intellia Contacts:
Media:Jennifer Mound SmoterSenior Vice
PresidentExternal Affairs & Communications+1
857-706-1071jenn.smoter@intelliatx.com
Lynnea OlivarezAssociate DirectorExternal Affairs &
Communications+1 956-330-1917lynnea.olivarez@intelliatx.com
Investors:Lindsey TrickettVice
PresidentInvestor Relations+1
857-285-6211lindsey.trickett@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024